

WELTZIEN LOURDES

Form 3

April 25, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

WELTZIEN LOURDES

(Last) (First) (Middle)

3471 RIVER HILLS DRIVE

(Street)

CINCINNATI, OH 45244

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

04/24/2018

3. Issuer Name and Ticker or Trading Symbol
 MERIDIAN BIOSCIENCE INC [VIVO]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 Executive VP, Life Science

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

36,685

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D) or Indirect

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Date Exercisable Expiration Date

Title Amount or Number of

Edgar Filing: WELTZIEN LOURDES - Form 3

				Shares		(I) (Instr. 5)	
Stock Options (Right to Buy)	Â (1)	10/01/2018	Common Stock	5,000	\$ 29.55	D	Â
Stock Options (Right to Buy)	Â (2)	07/01/2026	Common Stock	10,000	\$ 19.66	D	Â
Stock Options (Right to Buy)	Â (3)	11/08/2027	Common Stock	12,500	\$ 14.65	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
WELTZIEN LOURDES 3471 RIVER HILLS DRIVE CINCINNATI, OH 45244	Â	Â	Â Executive VP, Life Science	Â

Signatures

/s/ Melissa A. Lueke as Attorney-in-Fact for Lourdes G. Weltzien

04/25/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These non-qualified options were awarded under the 2004 Equity Compensation Plan and are fully vested and exercisable.
- (2) These non-qualified options were awarded under the 2012 Stock Incentive Plan and vest in four equal installments from the date of grant until fully vested on July 1, 2020.
- (3) These non-qualified options were awarded under the 2012 Stock Incentive Plan and cliff vest on November 15, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.